Pretreatment alanine transaminase level may not be the most important predictor of HBeAg loss in the older patient

Liver International

Volumn 29, Issue 2, 2009, Pages 231-236

  Lee, Jung Il ^a   Park, Hyun Joo ^a   Lee, Jin Woo ^a   Kim, Young Soo ^a   Jeong, Seok ^a   Lee, Don Haeng ^a   Kim, Hyung Gil ^a   Shin, Yong Woon ^a   Kwon, Kye Sook ^a  

^a Inha University School of Medicine   (South Korea)

Author keywords

Aminotransferase level; Chronic hepatitis B; Predictor of HBeAg loss; Prolonged HBeAg positive serum

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; RETROSPECTIVE STUDY; SEROCONVERSION;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; HEPATITIS B; HEPATITIS B E ANTIGENS; HUMANS; KOREA; LAMIVUDINE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 58149493026     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01815.x     Document Type: Article

References (27)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
2. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
3. EASL Jury. EASL international consensus conference on hepatitis B. 13-14 September 2002: Geneva, Switzerland, consensus statement (long version). J Hepatol 2003; 38: 533-40.
4. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005; 25: 472-89.
5. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30: 770-4.
6. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBe Ag loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-94.
7. Yang PM, Chen DS, Lai MY, et al. Clinicopathologic studies of asymptomatic HbsAg carriers: With special emphasis on carriers older than 40 years. Hepatogastroenterology 1987; 34: 251-4.
8. Lok AS, Ghany MG, Watson G, Ayola B. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepat 1998; 5: 171-8.
9. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001; 34: 1021-6.
10. Yoon SK, Jang JW, Kim CW, et al. Long-term results of lamivudine monotherapy in Korean patients with HbeAg-positive chronic hepatitis B: response and relapse rates and factors related to durability of HbeAg seroconversion. Intervirology 2005; 48: 341-9.
11. Hann HW, Funk MJ, Rosenberg DM, Davis R. Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B. J Gastroenterol Hepatol 2005; 20: 433-40.
12. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52.
13. Wolters LMM, Hansen BE, Niesters HGM, et al. The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patient treatment with lamivudine. J Hepatol 2002; 37: 253-8.
14. Liaw YF, Tsai SL. Pathogenesis and clinical significance of acute exacerbations and remissions in patients with chronic hepatitis B virus infection. Viral Hep Rev 1997; 3: 143-54.
15. Yuen MF, Sablon E, Libbrecht E, et al. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antiviral Ther 2006; 11: 779-86.
16. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: Special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepatol 2006; 14: 147-52.
17. Chu CM, Sheen IS, Lin SM, Liaw YF. Sex difference in chronic hepatitis B virus infection; studies of serum HBeAg and alanine aminotransferase levels in 10431 asymptomatic Chinese HBsAg carriers. Clin Infect Dis 1993; 16: 709-13.
18. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 829-34.
19. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
20. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biologic gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
21. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 989-91.
22. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797-803.
23. Furusyo N, Takeoka H, Toyoda K, et al. Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: A project of Kyushu University Liver Disease Study. World J Gastroenterol 2006; 28: 561-7.
24. Yuen MF, Yuan HJ, Wong KH, et al. Prognostic determinants for chronic hepatitis B in Asians: Therapeutic implications. Gut 2005; 54: 1610-4.
25. Bae SH, Yoon SK, Jang JW, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005; 20: 816-20.
26. Kim H, Jee YM, Song BC, et al. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. Intervirology 2007; 50: 52-7.
27. Kim H, Jee YM, Song BC, et al. Analysis of hepatitis B virus quasispecies distribution in a Korean chronic patient based on the full genome sequence. J Med Virol 2007; 79: 212-9.